SoftBank and Alexandria Real Estate Equities helped the Bloomberg-backed genetic medicine developer raise series C funding to further expand its pipeline of RNA therapies.
Internet and telecommunications group SoftBank’s Vision Fund 2 led a $180m series C round on Wednesday for Deep Genomics, a Canada-based RNA therapy developer.
The round also featured Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as investment and financial services group Fidelity, Canadian Pension Plan Investment Board, Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures.
Founded in 2015, Deep Genomics uses artificial intelligence and machine learning…
